The southern African country has so far administered about 31,000
doses of the AstraZeneca vaccine, the only vaccine it has started
rolling out.
India donated 30,000 doses of the vaccine that were manufactured by
the Serum Institute of India (SII), and Botswana bought 33,000 doses
that were made in South Korea from global vaccine distribution
scheme COVAX.
The two people who died had taken the shots made in India.
AstraZeneca and the SII did not immediately respond to requests for
comment from Reuters. Botswana's health ministry did not say how the
people died.
Millions of doses of the AstraZeneca shot have been safely
administered around the world. The European Medicines Agency
received reports of 169 cases of the rare brain blood clot by early
April, after 34 million doses had been administered, Sabine Straus,
chair of the EMA's safety committee, said.
Most of the cases reported had occurred in women under 60.
The Botswana health ministry said in a statement late on Sunday that
the two deaths were of elderly people. It did not elaborate. The
AstraZeneca doses were made in India and are being distributed under
the brand name COVISHIELD.

"The ministry has referred the matter to the regulator being BOMRA
for immediate investigation. It is expected that BOMRA investigation
will seek to establish the cause of two deaths as well as whether
they are in any way linked to the COVID vaccine which was
administered," the statement read.
[to top of second column] |
 It advised the public to remain
calm and said people who were recovering from
recent severe illness should consider delaying
getting the vaccine. Botswana's
investigation comes after Europe's drug regulator said it had found
a possible link between AstraZeneca's vaccine and very rare cases of
blood clots.

Experts say that, even if a causal link is proved between the
vaccine and blood clots, the risks of getting a serious clot are
minute compared to the risks from possible COVID-19 infection, which
can cause similar clots along with other serious symptoms.
Botswana has recorded around 40,000 coronavirus cases and 630 deaths
during the pandemic, few by comparison with many other countries
around the world, but its diamond-driven economy was hit hard last
year, contracting almost 8%.
AstraZeneca's shot is the cheapest and most readily available. It
does not need to be kept at extremely cold temperatures unlike some
other vaccines, making it a mainstay of many vaccination programmes
in the developing world.
(Reporting by Brian Benza; Additional reporting by Ludwig Burger in
Frankfurt and Euan Rocha in Mumbai; Editing by Alexander Winning)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |